Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 119Neoplasms 100Lung Neoplasms 66Colorectal Neoplasms 60Carcinoma, Hepatocellular 56Carcinoma, Non-Small-Cell Lung 51Prostatic Neoplasms 47Pancreatic Neoplasms 37Uterine Cervical Neoplasms 35Stomach Neoplasms 29Ovarian Neoplasms 28Disease 28Rectal Neoplasms 27Multiple Myeloma 24Leukemia, Myeloid, Acute 21Head and Neck Neoplasms 21Endometrial Neoplasms 21Recurrence 20Esophageal Neoplasms 19Colonic Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasm Metastasis 17Glioblastoma 17Melanoma 15Lymphoma 15Glioma 15Cholangiocarcinoma 14Urinary Bladder Neoplasms 12Neoplasm, Residual 12Liver Neoplasms 12

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Observational × HER2 Overexpression × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡